Product ApprovalThe forecast for FY3/29 assumes Viltepso will remain on the US market and gain approval in China and the EU, indicating expansion opportunities.
Research And DevelopmentThe company plans to invest ¥190bn in R&D over five years, indicating a strong commitment to innovation and development.
Revenue ForecastThe company's newly announced FY3/29 revenue target of ¥230bn significantly exceeds analyst estimates, showcasing potential strong growth.